Overview

Rituximab in IgG4-RD: A Phase 1-2 Trial

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and effectiveness of rituximab in IgG4-RD.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Genentech, Inc.
Treatments:
Immunoglobulin G
Rituximab